Acucela gets European orphan designation for emixustat to treat Stargardt disease

This article was originally published here

In January 2017, Acucela had received orphan drug designation from the US Food and Drug Administration (FDA) for emixustat to treat Stargardt disease. Stargardt disease is a rare

The post Acucela gets European orphan designation for emixustat to treat Stargardt disease appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply